Microvascular Tissues

Executive Summary

Microvascular Tissues, Inc. is a regenerative medicine company focused on developing mVASC®, a human cadaver-derived extracellular matrix (ECM) disk designed to repair microvascular structures. The product is sourced from hypodermal tissue containing arterioles, capillaries, and venules, and is processed via lyophilization and terminal sterilization to achieve a sterility assurance level (SAL) of 10⁻⁶. mVASC aims to address critical unmet needs in cardiovascular and microvascular repair by providing a scaffold that promotes tissue regeneration. As a private company based in Jackson, USA, Microvascular Tissues has not disclosed funding or valuation details, and its stage remains unspecified. The product's unique mechanism and clinically validated sterilization process position it as a potential candidate for regulatory advancement, though no public clinical or regulatory milestones have been announced. The company's success will depend on securing FDA clearance or approval, demonstrating clinical efficacy, and establishing partnerships for manufacturing and distribution.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance or IDE Approval for mVASC40% success
• Q2 2026Publication of Preclinical or Clinical Data60% success
• Q3 2026Strategic Partnership or Licensing Agreement35% success